Fan Jia, Zhou Jian, Wu Zhi-Quan, Qiu Shuang-Jian, Wang Xiao-Ying, Shi Ying-Hong, Tang Zhao-You
Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Yixueyuan Road, Shanghai 200032, China.
World J Gastroenterol. 2005 Feb 28;11(8):1215-9. doi: 10.3748/wjg.v11.i8.1215.
To evaluate the efficacy of different treatment strategies for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) and investigate factors influencing prognosis.
One hundred and seventy-nine HCC patients with macroscopic PVTT were enrolled in this study. They were divided into four groups and underwent different treatments: conservative treatment group (n = 18), chemotherapy group (n = 53), surgical resection group (n = 24) and surgical resection with postoperative chemotherapy group (n = 84). Survival rates of the patients were analyzed by the Kaplan-Meier method. A log-rank analysis was performed to identify group differences. Cox's proportional hazards model was used to analyze variables associated with survival.
The mean survival periods of the patients in four groups were 3.6, 7.3, 10.1, and 15.1 mo respectively. There were significant differences in the survival rates among the groups. The survival rates at 0.5-, 1-, 2-, and 3-year in surgical resection with postoperative chemotherapy group were 55.8%, 39.3%, 30.4%, and 15.6% respectively, which were significantly higher than those of other groups (P<0.001). Multivariate analysis revealed that the strategy of treatment (P<0.001) and the number of chemotherapy cycles (P = 0.012) were independent survival predictors for patients with HCC and PVTT.
Surgical resection of HCC and PVTT combined with postoperative chemotherapy or chemoembolization is the most effective therapeutic strategy for the patients who can tolerate operation. Multiple chemotherapeutic courses should be given postoperatively to the patients with good hepatic function reserve.
评估不同治疗策略对伴有门静脉癌栓(PVTT)的肝细胞癌(HCC)的疗效,并探讨影响预后的因素。
179例伴有肉眼可见PVTT的HCC患者纳入本研究。他们被分为四组并接受不同治疗:保守治疗组(n = 18)、化疗组(n = 53)、手术切除组(n = 24)和术后化疗的手术切除组(n = 84)。采用Kaplan-Meier法分析患者生存率。进行对数秩检验以确定组间差异。采用Cox比例风险模型分析与生存相关的变量。
四组患者的平均生存期分别为3.6、7.3、10.1和15.1个月。组间生存率有显著差异。术后化疗的手术切除组0.5年、1年、2年和3年的生存率分别为55.8%、39.3%、30.4%和15.6%,显著高于其他组(P<0.001)。多因素分析显示,治疗策略(P<0.001)和化疗周期数(P = 0.012)是HCC合并PVTT患者的独立生存预测因素。
对于能够耐受手术的患者,手术切除HCC和PVTT并联合术后化疗或化疗栓塞是最有效的治疗策略。对于肝功能储备良好的患者,术后应给予多个化疗疗程。